{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:12:37Z","timestamp":1790673157470,"version":"4.1.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gennova Biopharmaceuticals Ltd, Pune, Maharashtra, India","award":["Corporate social responsibility (CSR) funding"],"award-info":[{"award-number":["Corporate social responsibility (CSR) funding"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04158-8","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T18:35:29Z","timestamp":1764009329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ganglioside therapy in cancer molecular insights and therapeutic opportunities"],"prefix":"10.1007","volume":"16","author":[{"given":"Avisek","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sounak","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham Raj","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishek","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"4158_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.572965","volume":"14","author":"S Sipione","year":"2020","unstructured":"Sipione S, et al. Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci. 2020;14:572965.","journal-title":"Front Neurosci"},{"key":"4158_CR2","doi-asserted-by":"publisher","first-page":"1282572","DOI":"10.3389\/fphar.2023.1282572","volume":"14","author":"A Sarkar","year":"2023","unstructured":"Sarkar A, Banerjee S, Biswas K. Multi-dimensional role of gangliosides in modulating cancer hallmarks and their prospects in targeted cancer therapy. Front Pharmacol. 2023;14:1282572.","journal-title":"Front Pharmacol"},{"key":"4158_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/bs.mie.2017.06.016","volume":"598","author":"Y Xu","year":"2018","unstructured":"Xu Y, Uddin N, Wagner GK. Covalent probes for carbohydrate-active enzymes: from glycosidases to glycosyltransferases. Methods Enzymol. 2018;598:237\u201365.","journal-title":"Methods Enzymol"},{"issue":"13","key":"4158_CR4","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/cbic.201600705","volume":"18","author":"S Groux-Degroote","year":"2017","unstructured":"Groux-Degroote S, Guerardel Y, Delannoy P. Gangliosides: structures, biosynthesis, analysis, and roles in cancer. ChemBioChem. 2017;18(13):1146\u201354.","journal-title":"ChemBioChem"},{"issue":"5","key":"4158_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1194\/jlr.R300020-JLR200","volume":"45","author":"RK Yu","year":"2004","unstructured":"Yu RK, et al. Regulation of ganglioside biosynthesis in the nervous system. J Lipid Res. 2004;45(5):783\u201393.","journal-title":"J Lipid Res"},{"issue":"3","key":"4158_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1074\/jbc.RA118.004485","volume":"294","author":"A Banerjee","year":"2019","unstructured":"Banerjee A, et al. Elevated histone H3 acetylation and loss of the Sp1-HDAC1 complex de-repress the GM2-synthase gene in renal cell carcinoma. J Biol Chem. 2019;294(3):1005\u201318.","journal-title":"J Biol Chem"},{"issue":"9","key":"4158_CR7","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.21873\/anticanres.16593","volume":"43","author":"C Higashi","year":"2023","unstructured":"Higashi C, et al. Ganglioside GD2 expression is associated with unfavorable prognosis in early triple-negative breast cancer. Anticancer Res. 2023;43(9):4045\u201353.","journal-title":"Anticancer Res"},{"issue":"2","key":"4158_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/156800910791054167","volume":"10","author":"F Navid","year":"2010","unstructured":"Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets. 2010;10(2):200\u20139.","journal-title":"Curr Cancer Drug Targets"},{"issue":"8","key":"4158_CR9","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.4049\/jimmunol.0900259","volume":"183","author":"S Biswas","year":"2009","unstructured":"Biswas S, et al. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol. 2009;183(8):5050\u20138.","journal-title":"J Immunol"},{"key":"4158_CR10","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.bbamcr.2016.04.004","volume":"1863","author":"M Kundu","year":"2016","unstructured":"Kundu M, et al. Ganglioside GM2 mediates migration of tumor cells by interacting with integrin and modulating the downstream signaling pathway. Biochim Biophys Acta. 2016;1863:1472\u201389.","journal-title":"Biochim Biophys Acta"},{"key":"4158_CR11","doi-asserted-by":"publisher","first-page":"9048","DOI":"10.1038\/srep09048","volume":"5","author":"B Mahata","year":"2015","unstructured":"Mahata B, et al. TALEN mediated targeted editing of GM2\/GD2-synthase gene modulates anchorage independent growth by reducing anoikis resistance in mouse tumor cells. Sci Rep. 2015;5:9048.","journal-title":"Sci Rep"},{"issue":"3","key":"4158_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s10555-023-10108-z","volume":"42","author":"I van der Haar Avila","year":"2023","unstructured":"van der Haar Avila I, Windhouwer B, van Vliet SJ. Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment. Cancer Metastasis Rev. 2023;42(3):941\u201358.","journal-title":"Cancer Metastasis Rev"},{"key":"4158_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ijms22116145","volume":"22","author":"S Groux-Degroote","year":"2021","unstructured":"Groux-Degroote S, Delannoy P. Cancer-associated glycosphingolipids as tumor markers and targets for cancer immunotherapy. Int J Mol Sci. 2021;22:11.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4158_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10719-019-09885-z","volume":"36","author":"Q Li","year":"2019","unstructured":"Li Q, et al. Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker. Glycoconj J. 2019;36(5):419\u201328.","journal-title":"Glycoconj J"},{"issue":"8","key":"4158_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/biom9080311","volume":"9","author":"S Cavdarli","year":"2019","unstructured":"Cavdarli S, Groux-Degroote S, Delannoy P. Gangliosides: the double-edge sword of neuro-ectodermal derived tumors. Biomolecules. 2019;9(8):311.","journal-title":"Biomolecules"},{"key":"4158_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fimmu.2014.00325","volume":"5","author":"U Krengel","year":"2014","unstructured":"Krengel U, Bousquet PA. Molecular recognition of gangliosides and their potential for cancer immunotherapies. Front Immunol. 2014;5:325.","journal-title":"Front Immunol"},{"issue":"12 Pt 1","key":"4158_CR17","first-page":"5914","volume":"44","author":"G Schulz","year":"1984","unstructured":"Schulz G, et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44(12 Pt 1):5914\u201320.","journal-title":"Cancer Res"},{"issue":"6","key":"4158_CR18","first-page":"2642","volume":"45","author":"NK Cheung","year":"1985","unstructured":"Cheung NK, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985;45(6):2642\u20139.","journal-title":"Cancer Res"},{"issue":"3","key":"4158_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1200\/JCO.1986.4.3.363","volume":"4","author":"NK Cheung","year":"1986","unstructured":"Cheung NK, et al. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol. 1986;4(3):363\u20139.","journal-title":"J Clin Oncol"},{"key":"4158_CR20","doi-asserted-by":"publisher","first-page":"1249929","DOI":"10.3389\/fphar.2023.1249929","volume":"14","author":"P Machy","year":"2023","unstructured":"Machy P, Mortier E, Birkle S. Biology of GD2 ganglioside: implications for cancer immunotherapy. Front Pharmacol. 2023;14:1249929.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4158_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/jcm12030754","volume":"12","author":"Q Li","year":"2023","unstructured":"Li Q, et al. Long-term survival of neuroblastoma patients receiving surgery, chemotherapy, and radiotherapy: a propensity score matching study. J Clin Med. 2023;12(3):754.","journal-title":"J Clin Med"},{"issue":"8","key":"4158_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1358\/dof.2010.35.8.1513490","volume":"35","author":"RK Yang","year":"2010","unstructured":"Yang RK, Sondel PM. Anti-GD2 strategy in the treatment of neuroblastoma. Drugs Future. 2010;35(8):665.","journal-title":"Drugs Future"},{"issue":"1","key":"4158_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13046-022-02523-x","volume":"41","author":"YL Sha","year":"2022","unstructured":"Sha YL, et al. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met\/AKT\/mTOR\/IRF-1 axis in neuroblastoma. J Exp Clin Cancer Res. 2022;41(1):314.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4\u20136","key":"4158_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000218188","volume":"23","author":"J Xu","year":"2009","unstructured":"Xu J, et al. Neural ganglioside GD2 identifies a subpopulation of mesenchymal stem cells in umbilical cord. Cell Physiol Biochem. 2009;23(4\u20136):415\u201324.","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"4158_CR25","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2217\/imt-2016-0021","volume":"8","author":"Z Perez Horta","year":"2016","unstructured":"Perez Horta Z, Goldberg JL, Sondel PM. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy. 2016;8(9):1097\u2013117.","journal-title":"Immunotherapy"},{"issue":"8","key":"4158_CR26","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","volume":"27","author":"AL Yu","year":"2021","unstructured":"Yu AL, et al. Long-term follow-up of a phase III study of ch1418 (Dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021;27(8):2179\u201389.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4158_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11523-022-00930-w","volume":"18","author":"J Balaguer","year":"2023","unstructured":"Balaguer J, et al. Recent evidence-based clinical guide for the use of Dinutuximab Beta in pediatric patients with neuroblastoma. Target Oncol. 2023;18(1):77\u201393.","journal-title":"Target Oncol"},{"issue":"9","key":"4158_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092535","volume":"15","author":"J Mora","year":"2023","unstructured":"Mora J, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in first complete remission under compassionate use-updated outcome report. Cancers (Basel). 2023;15(9):e29121.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4158_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/pbc.26184","volume":"64","author":"R Schumacher-Kuckelkorn","year":"2017","unstructured":"Schumacher-Kuckelkorn R, et al. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence. Pediatr Blood Cancer. 2017;64(1):46\u201356.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"4158_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/1093526617723972","volume":"21","author":"T Terzic","year":"2018","unstructured":"Terzic T, et al. Expression of disialoganglioside (GD2) in neuroblastic tumors: a prognostic value for patients treated with anti-GD2 immunotherapy. Pediatr Dev Pathol. 2018;21(4):355\u201362.","journal-title":"Pediatr Dev Pathol"},{"key":"4158_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/jitc-2020-002293","volume":"9","author":"A Dondero","year":"2021","unstructured":"Dondero A, et al. Multiparametric flow cytometry highlights B7\u2013H3 as a novel diagnostic\/therapeutic target in GD2neg\/low neuroblastoma variants. J Immunother Cancer. 2021;9:4.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"4158_CR32","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","volume":"3","author":"NW Mabe","year":"2022","unstructured":"Mabe NW, et al. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nat Cancer. 2022;3(8):976\u201393.","journal-title":"Nat Cancer"},{"issue":"2","key":"4158_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","volume":"28","author":"J Theruvath","year":"2022","unstructured":"Theruvath J, et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med. 2022;28(2):333\u201344.","journal-title":"Nat Med"},{"key":"4158_CR34","first-page":"1","volume":"13","author":"ME Keyel","year":"2019","unstructured":"Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics. 2019;13:1\u201312.","journal-title":"Biologics"},{"issue":"9","key":"4158_CR35","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2(9):904\u201318.","journal-title":"Nat Cancer"},{"issue":"2","key":"4158_CR36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoncol.2022.5999","volume":"9","author":"IY Cheung","year":"2023","unstructured":"Cheung IY, et al. Effect of oral beta-glucan on antibody response to ganglioside vaccine in patients with high-risk neuroblastoma: a phase 2 randomized clinical trial. JAMA Oncol. 2023;9(2):242\u201350.","journal-title":"JAMA Oncol"},{"issue":"24","key":"4158_CR37","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.3390\/cancers13246265","volume":"13","author":"FI Cardenas","year":"2021","unstructured":"Cardenas FI, et al. Phase I trial of oral yeast-derived \u03b2-glucan to enhance Anti-GD2 immunotherapy of resistant high-risk neuroblastoma. Cancers (Basel). 2021;13(24):6265.","journal-title":"Cancers (Basel)"},{"key":"4158_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/978-3-031-59815-9_37","volume":"1448","author":"D Barrett","year":"2024","unstructured":"Barrett D. IL-6 blockade in cytokine storm syndromes. Adv Exp Med Biol. 2024;1448:565\u201372.","journal-title":"Adv Exp Med Biol"},{"key":"4158_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.","journal-title":"Front Pharmacol"},{"issue":"14","key":"4158_CR40","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284\u201395.","journal-title":"N Engl J Med"},{"key":"4158_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03874-6","author":"F Locatelli","year":"2025","unstructured":"Locatelli F, et al. GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03874-6.","journal-title":"Nat Med"},{"issue":"1","key":"4158_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"4158_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003897","author":"L Reppel","year":"2022","unstructured":"Reppel L, et al. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003897.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4158_CR44","first-page":"4244","volume":"61","author":"S Yoshida","year":"2001","unstructured":"Yoshida S, et al. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 2001;61(10):4244\u201352.","journal-title":"Cancer Res"},{"issue":"11","key":"4158_CR45","doi-asserted-by":"publisher","first-page":"12569","DOI":"10.1002\/cam4.5907","volume":"12","author":"T Sasaki","year":"2023","unstructured":"Sasaki T, et al. Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model. Cancer Med. 2023;12(11):12569\u201380.","journal-title":"Cancer Med"},{"issue":"11","key":"4158_CR46","volume":"3","author":"Q Chu","year":"2022","unstructured":"Chu Q, et al. BMS-986012, an anti-Fucosyl-GM1 monoclonal antibody as monotherapy or in combination with Nivolumab in relapsed\/refractory SCLC: results from a first-in-human phase 1\/2 study. JTO Clin Res Rep. 2022;3(11):100400.","journal-title":"JTO Clin Res Rep"},{"key":"4158_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","volume":"166","author":"MJ Edelman","year":"2022","unstructured":"Edelman MJ, et al. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer. Lung Cancer. 2022;166:135\u201342.","journal-title":"Lung Cancer"},{"issue":"3","key":"4158_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.102923","volume":"299","author":"K Horejsi","year":"2023","unstructured":"Horejsi K, et al. Comprehensive characterization of complex glycosphingolipids in human pancreatic cancer tissues. J Biol Chem. 2023;299(3):102923.","journal-title":"J Biol Chem"},{"key":"4158_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007805","author":"K Boelaars","year":"2023","unstructured":"Boelaars K, et al. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007805.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4158_CR50","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","volume":"12","author":"E Rodriguez","year":"2021","unstructured":"Rodriguez E, et al. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat Commun. 2021;12(1):1270.","journal-title":"Nat Commun"},{"issue":"19","key":"4158_CR51","doi-asserted-by":"publisher","first-page":"31592","DOI":"10.18632\/oncotarget.16363","volume":"8","author":"G Orsi","year":"2017","unstructured":"Orsi G, et al. Gd2 expression in breast cancer. Oncotarget. 2017;8(19):31592\u2013600.","journal-title":"Oncotarget"},{"issue":"6","key":"4158_CR52","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1172\/JCI59735","volume":"122","author":"VL Battula","year":"2012","unstructured":"Battula VL, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012;122(6):2066\u201378.","journal-title":"J Clin Invest"},{"key":"4158_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001197","author":"S Ly","year":"2021","unstructured":"Ly S, et al. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2(+) breast cancer stem-like cells. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001197.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4158_CR54","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount CW, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3\u2013K27M(+) diffuse midline gliomas. Nat Med. 2018;24(5):572\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"4158_CR55","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-18-0399","volume":"17","author":"K Nguyen","year":"2018","unstructured":"Nguyen K, et al. ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway. Mol Cancer Ther. 2018;17(12):2689\u2013701.","journal-title":"Mol Cancer Ther"},{"issue":"29","key":"4158_CR56","doi-asserted-by":"publisher","first-page":"47454","DOI":"10.18632\/oncotarget.17665","volume":"8","author":"YJ Liang","year":"2017","unstructured":"Liang YJ, et al. Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. Oncotarget. 2017;8(29):47454\u201373.","journal-title":"Oncotarget"},{"issue":"23","key":"4158_CR57","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/onc.2014.245","volume":"34","author":"TR Sarkar","year":"2015","unstructured":"Sarkar TR, et al. Gd3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 2015;34(23):2958\u201367.","journal-title":"Oncogene"},{"key":"4158_CR58","doi-asserted-by":"crossref","unstructured":"Bhat, A.M., et al., GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior. bioRxiv, 2024.","DOI":"10.1101\/2023.03.18.533299"},{"issue":"1","key":"4158_CR59","doi-asserted-by":"publisher","first-page":"13523","DOI":"10.1038\/s41598-024-60052-3","volume":"14","author":"AM Bhat","year":"2024","unstructured":"Bhat AM, et al. Gd2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior. Sci Rep. 2024;14(1):13523.","journal-title":"Sci Rep"},{"issue":"56","key":"4158_CR60","doi-asserted-by":"publisher","first-page":"95620","DOI":"10.18632\/oncotarget.21038","volume":"8","author":"V Vantaku","year":"2017","unstructured":"Vantaku V, et al. Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. Oncotarget. 2017;8(56):95620\u201331.","journal-title":"Oncotarget"},{"issue":"2","key":"4158_CR61","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/0008-8749(88)90104-9","volume":"111","author":"DS Hoon","year":"1988","unstructured":"Hoon DS, Irie RF, Cochran AJ. Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. Cell Immunol. 1988;111(2):410\u20139.","journal-title":"Cell Immunol"},{"issue":"8","key":"4158_CR62","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1346-8138.1991.tb03114.x","volume":"18","author":"N Morioka","year":"1991","unstructured":"Morioka N, et al. Gangliosides inhibit the proliferation of human T cells stimulated with interleukin-4 or interleukin-2. J Dermatol. 1991;18(8):447\u201353.","journal-title":"J Dermatol"},{"issue":"13","key":"4158_CR63","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1158\/0008-5472.CAN-06-0250","volume":"66","author":"K Biswas","year":"2006","unstructured":"Biswas K, et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res. 2006;66(13):6816\u201325.","journal-title":"Cancer Res"},{"issue":"12","key":"4158_CR64","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1158\/0008-5472.CAN-04-4395","volume":"65","author":"A Chahlavi","year":"2005","unstructured":"Chahlavi A, et al. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res. 2005;65(12):5428\u201338.","journal-title":"Cancer Res"},{"issue":"10","key":"4158_CR65","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.4049\/jimmunol.139.10.3295","volume":"139","author":"H Offner","year":"1987","unstructured":"Offner H, Thieme T, Vandenbark AA. Gangliosides induce selective modulation of CD4 from helper T lymphocytes. J Immunol. 1987;139(10):3295\u2013305.","journal-title":"J Immunol"},{"issue":"4","key":"4158_CR66","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00262-005-0041-6","volume":"55","author":"J de Leon","year":"2006","unstructured":"de Leon J, et al. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother. 2006;55(4):443\u201350.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"4158_CR67","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-3083.1995.tb03547.x","volume":"41","author":"M Sorice","year":"1995","unstructured":"Sorice M, et al. Monosialoganglioside GM3 induces CD4 internalization in human peripheral blood T lymphocytes. Scand J Immunol. 1995;41(2):148\u201356.","journal-title":"Scand J Immunol"},{"key":"4158_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.651048","volume":"12","author":"M Kume","year":"2021","unstructured":"Kume M, et al. Ganglioside GD3 may suppress the functional activities of benign skin T cells in cutaneous T-cell lymphoma. Front Immunol. 2021;12:651048.","journal-title":"Front Immunol"},{"issue":"2","key":"4158_CR69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1006\/clin.1996.0068","volume":"79","author":"H Kimata","year":"1996","unstructured":"Kimata H, Yoshida A. Inhibition of spontaneous immunoglobulin production by ganglioside GM2 in human B cells. Clin Immunol Immunopathol. 1996;79(2):197\u2013202.","journal-title":"Clin Immunol Immunopathol"},{"issue":"10","key":"4158_CR70","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0301-472X(99)00093-4","volume":"27","author":"N Kanda","year":"1999","unstructured":"Kanda N, Tamaki K. Ganglioside GD1b supresses immunoglobulin production by human peripheral blood mononuclear cells. Exp Hematol. 1999;27(10):1487\u201393.","journal-title":"Exp Hematol"},{"issue":"7903","key":"4158_CR71","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934\u201341.","journal-title":"Nature"},{"issue":"1","key":"4158_CR72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12672-023-00643-0","volume":"14","author":"WS Ju","year":"2023","unstructured":"Ju WS, et al. 7,8-dihydroxyflavone induces mitochondrial apoptosis and down-regulates the expression of ganglioside GD3 in malignant melanoma cells. Discov Oncol. 2023;14(1):36.","journal-title":"Discov Oncol"},{"key":"4158_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129905","author":"K El Malki","year":"2023","unstructured":"El Malki K, et al. Glucosylceramide synthase inhibitors induce ceramide accumulation and sensitize H3K27 mutant diffuse midline glioma to irradiation. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24129905.","journal-title":"Int J Mol Sci"},{"key":"4158_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26185673","author":"S Perez","year":"2021","unstructured":"Perez S, Fu CW, Li WS. Sialyltransferase inhibitors for the treatment of cancer metastasis: current challenges and future perspectives. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26185673.","journal-title":"Molecules"},{"issue":"1","key":"4158_CR75","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s42003-023-05324-w","volume":"6","author":"N Miwa","year":"2023","unstructured":"Miwa N, et al. Dicalcin suppresses invasion and metastasis of mammalian ovarian cancer cells by regulating the ganglioside-Erk1\/2 axis. Commun Biol. 2023;6(1):1015.","journal-title":"Commun Biol"},{"key":"4158_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.012","author":"A Banerjee","year":"2025","unstructured":"Banerjee A, et al. Molecular landscape and therapeutic strategies of lung cancer lineage plasticity. J Thorac Oncol. 2025. https:\/\/doi.org\/10.1016\/j.jtho.2025.06.012.","journal-title":"J Thorac Oncol"},{"issue":"20","key":"4158_CR77","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1073\/pnas.1604721113","volume":"113","author":"SC Yeh","year":"2016","unstructured":"Yeh SC, et al. Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity. Proc Natl Acad Sci U S A. 2016;113(20):5592\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"4158_CR78","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1073\/pnas.1302825110","volume":"110","author":"YJ Liang","year":"2013","unstructured":"Liang YJ, et al. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A. 2013;110(13):4968\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"4158_CR79","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41416-021-01636-y","volume":"126","author":"A Jaggupilli","year":"2022","unstructured":"Jaggupilli A, et al. Metabolic stress induces GD2(+) cancer stem cell-like phenotype in triple-negative breast cancer. Br J Cancer. 2022;126(4):615\u201327.","journal-title":"Br J Cancer"},{"issue":"3","key":"4158_CR80","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212\u201326.","journal-title":"Trends Cell Biol"},{"issue":"22","key":"4158_CR81","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1158\/0008-5472.CAN-16-3521","volume":"77","author":"JT George","year":"2017","unstructured":"George JT, et al. Survival outcomes in cancer patients predicted by a partial EMT gene expression scoring metric. Cancer Res. 2017;77(22):6415\u201328.","journal-title":"Cancer Res"},{"issue":"12","key":"4158_CR82","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","volume":"21","author":"KT Schjoldager","year":"2020","unstructured":"Schjoldager KT, et al. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21(12):729\u201349.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"4158_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111181","volume":"40","author":"C Cumin","year":"2022","unstructured":"Cumin C, et al. Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways. Cell Rep. 2022;40(7):111181.","journal-title":"Cell Rep"},{"issue":"9","key":"4158_CR84","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1111\/cas.15032","volume":"112","author":"Y Ohkawa","year":"2021","unstructured":"Ohkawa Y, et al. Lack of GD3 synthase (St8sia1) attenuates malignant properties of gliomas in genetically engineered mouse model. Cancer Sci. 2021;112(9):3756\u201368.","journal-title":"Cancer Sci"},{"key":"4158_CR85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fonc.2016.00033","volume":"6","author":"X Li","year":"2016","unstructured":"Li X, et al. Role of glycans in cancer cells undergoing epithelial-mesenchymal transition. Front Oncol. 2016;6:33.","journal-title":"Front Oncol"},{"issue":"2","key":"4158_CR86","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s13238-020-00741-7","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, et al. Role of glycosylation in TGF-beta signaling and epithelial-to-mesenchymal transition in cancer. Protein Cell. 2021;12(2):89\u2013106.","journal-title":"Protein Cell"},{"issue":"2","key":"4158_CR87","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021110553","volume":"42","author":"J Zhang","year":"2023","unstructured":"Zhang J, et al. ST3GAL5-catalyzed gangliosides inhibit TGF-beta-induced epithelial-mesenchymal transition via TbetaRI degradation. EMBO J. 2023;42(2):e110553.","journal-title":"EMBO J"},{"issue":"1","key":"4158_CR88","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12885-018-4084-4","volume":"18","author":"MS Wegner","year":"2018","unstructured":"Wegner MS, et al. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1). BMC Cancer. 2018;18(1):153.","journal-title":"BMC Cancer"},{"key":"4158_CR89","doi-asserted-by":"publisher","first-page":"1382931","DOI":"10.3389\/fimmu.2024.1382931","volume":"15","author":"S Di Matteo","year":"2024","unstructured":"Di Matteo S, et al. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells. Front Immunol. 2024;15:1382931.","journal-title":"Front Immunol"},{"issue":"34","key":"4158_CR90","doi-asserted-by":"publisher","first-page":"20836","DOI":"10.1074\/jbc.271.34.20836","volume":"271","author":"K Furukawa","year":"1996","unstructured":"Furukawa K, et al. Genomic organization and chromosomal assignment of the human beta1, 4-N-acetylgalactosaminyltransferase gene Identification of multiple transcription units. J Biol Chem. 1996;271(34):20836\u201344.","journal-title":"J Biol Chem"},{"issue":"6","key":"4158_CR91","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10719-016-9719-6","volume":"34","author":"Y Itokazu","year":"2017","unstructured":"Itokazu Y, Tsai YT, Yu RK. Epigenetic regulation of ganglioside expression in neural stem cells and neuronal cells. Glycoconj J. 2017;34(6):749\u201356.","journal-title":"Glycoconj J"},{"issue":"3","key":"4158_CR92","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10719-023-10108-9","volume":"40","author":"Y Yamamoto","year":"2023","unstructured":"Yamamoto Y, et al. Possible regulation of ganglioside GD3 synthase gene expression with DNA methylation in human glioma cells. Glycoconj J. 2023;40(3):323\u201332.","journal-title":"Glycoconj J"},{"issue":"3","key":"4158_CR93","first-page":"535","volume":"83","author":"P Zhang","year":"2021","unstructured":"Zhang P, et al. St8sia1-deficiency in mice alters tumor environments of gliomas, leading to reduced disease severity. Nagoya J Med Sci. 2021;83(3):535\u201349.","journal-title":"Nagoya J Med Sci"},{"issue":"5","key":"4158_CR94","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/j.1471-4159.2010.07042.x","volume":"116","author":"Y Suzuki","year":"2011","unstructured":"Suzuki Y, et al. Histone acetylation-mediated glycosyltransferase gene regulation in mouse brain during development. J Neurochem. 2011;116(5):874\u201380.","journal-title":"J Neurochem"},{"key":"4158_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246051","author":"C Paret","year":"2022","unstructured":"Paret C, et al. GD2 expression in medulloblastoma and neuroblastoma for personalized immunotherapy: a matter of subtype. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14246051.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4158_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038129","volume":"7","author":"A Tivnan","year":"2012","unstructured":"Tivnan A, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE. 2012;7(5):e38129.","journal-title":"PLoS ONE"},{"issue":"10","key":"4158_CR97","doi-asserted-by":"publisher","first-page":"16605","DOI":"10.18632\/oncotarget.15073","volume":"8","author":"A Tivnan","year":"2017","unstructured":"Tivnan A, et al. Anti-GD2-ch14.18\/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget. 2017;8(10):16605\u201320.","journal-title":"Oncotarget"},{"key":"4158_CR98","doi-asserted-by":"crossref","unstructured":"Rosenkrans, Z.T., et al., Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors. bioRxiv, 2024.","DOI":"10.1101\/2024.05.23.595624"},{"issue":"1","key":"4158_CR99","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1038\/s41467-024-51337-2","volume":"15","author":"G Pascual-Pasto","year":"2024","unstructured":"Pascual-Pasto G, et al. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma. Nat Commun. 2024;15(1):7141.","journal-title":"Nat Commun"},{"key":"4158_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004646","author":"DV Kalinovsky","year":"2022","unstructured":"Kalinovsky DV, et al. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004646.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4158_CR101","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1134\/S0006297925600395","volume":"90","author":"AO Makarova","year":"2025","unstructured":"Makarova AO, et al. Endocytosis properties of GD2-specific antibodies in tumor cells. Biochemistry (Mosc). 2025;90(3):424\u201335.","journal-title":"Biochemistry (Mosc)"},{"key":"4158_CR102","doi-asserted-by":"publisher","DOI":"10.1007\/s10719-024-10168-5","author":"E Khamrui","year":"2024","unstructured":"Khamrui E, et al. Emerging role of MAPK signaling in glycosphingolipid-associated tumorigenesis. Glycoconj J. 2024. https:\/\/doi.org\/10.1007\/s10719-024-10168-5.","journal-title":"Glycoconj J"},{"key":"4158_CR103","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.addr.2020.06.009","volume":"159","author":"Z Wu","year":"2020","unstructured":"Wu Z, et al. \u201cLipidomics\u201d: mass spectrometric and chemometric analyses of lipids. Adv Drug Deliv Rev. 2020;159:294\u2013307.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04158-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04158-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04158-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T23:02:57Z","timestamp":1767049377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04158-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4158"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04158-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is a review based on published literature, with no experimental work performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Avisek Banerjee declares they are a Guest Editor for Discover Oncology and confirms that they were not involved in the handling or decision-making of their own submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2292"}}